Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study

INTRODUCTION: Hypercoagulation is one the main features of COVID-19. It is induced by the hyperinflammatory response that shifts the balance of haemostasis towards pro-coagulation. Interleukin-6 (IL-6) antagonist therapy has been recommended in certain subgroups of critically ill patients with COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovács, Emőke Henrietta, Rottler, Máté, Dembrovszky, Fanni, Ocskay, Klementina, Szabó, László, Hegyi, Péter, Molnár, Zsolt, Tánczos, Krisztián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638747/
https://www.ncbi.nlm.nih.gov/pubmed/36332964
http://dx.doi.org/10.1136/bmjopen-2022-063856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638747/
https://www.ncbi.nlm.nih.gov/pubmed/36332964
http://dx.doi.org/10.1136/bmjopen-2022-063856

Ejemplares similares